SBIR TOPIC 431 - MOBILE ORAL-CANCER SCREENING AND TREATMENT (MOST) SYSTEM FOR LOW-RESOURCE SETTINGS

口腔和口咽鳞状细胞癌（OSCC）一起列为全球第六大常见癌症，它是一些低收入和中等收入国家（LMIC）最常见的癌症。低收入国家和发达国家农村地区的存活率低，主要是由于诊断晚，导致疾病在诊断时进展到晚期。 受两个不同的NIH UH 2/UH 3项目在检测和治疗前和早期口腔癌方面取得的成功的激励，Light Research Inc（LRI）提出开发并商业化一种新的集成移动的口腔癌筛查和治疗（MOST）系统，该系统针对低资源环境（LRS）进行了优化。它结合了双模式口腔癌筛查技术和基于光化学的FDA批准的光动力治疗（PDT）模式。我们将首先开发MOST系统（目标1），然后用小鼠皮下异种移植模型证明MOST系统的成像和治疗性能（目标2）。该项目意义重大，因为口腔癌的早期诊断和及时治疗可以减少疾病进展，降低发病率和死亡率，并降低成本。它解决了在LRS中筛查高危人群和治疗高危口腔癌前病变和恶性病变（OPML）和早期口腔癌患者的主要障碍。

Oral and oropharyngeal squamous cell carcinoma (OSCC) together rank as the sixth most common cancer worldwide, it is the most common cancer in some low- and middle- income countries (LMICs). The poor survival rate in LMICs and rural regions in developed countries is mainly due to late diagnosis and the resultant progression of disease to an advanced stage at diagnosis. Motivated by the successes in the two different NIH UH2/UH3 projects for detecting and treating pre- and early oral cancers, Light Research Inc (LRI) proposes to develop and commercialize a new integrated mobile oral-cancer screening and treatment (MOST) system, optimized for low-resource settings (LRS). It combines dual-modal oral cancer screening technology and photochemistry-based, FDA approved photodynamic therapy (PDT) modality. We will first develop the MOST system (Aim 1) and then demonstrate the imaging and treatment performance of MOST system with murine subcutaneous xenograft model (Aim 2). This project is significant because early diagnosis of oral cancers and timely treatment can reduce disease progression, reduce morbidity and mortality, and cut costs. It addresses the major barrier to screen high-risk population and treat patients with high risk oral premalignant and malignant lesions (OPML) and early-stage oral cancer in LRS.